Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03823703
Recruitment Status : Terminated (Suspended by sponsor, pending investigation of abnormal laboratory values in patients with NASH)
First Posted : January 30, 2019
Last Update Posted : October 6, 2021
Sponsor:
Information provided by (Responsible Party):
Corcept Therapeutics

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH).

Condition or disease Intervention/treatment Phase
Nonalcoholic Steatohepatitis (NASH) Drug: Miricorilant Drug: Placebo Phase 2

Detailed Description:

This is a randomized, double-blind, placebo-controlled study that will assess the safety efficacy and pharmacokinetics (PK) of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH).

Patients who meet the criteria for the Study CORT118335-860 will be randomized on Day 1 to receive 900 mg miricorilant, 600 mg miricorilant, or placebo for 12 weeks.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Subject, Investigator and Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
Actual Study Start Date : November 4, 2020
Actual Primary Completion Date : April 5, 2021
Actual Study Completion Date : April 5, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Miricorilant- 900 mg
Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 900 mg miricorilant once daily for 12 weeks.
 Drug: Miricorilant
Miricorilant 900 mg for oral dosing
Other Name: CORT118335
Experimental: Miricorilant- 600 mg
Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 600 mg miricorilant plus placebo once daily for 12 weeks.
 Drug: Miricorilant
Miricorilant 600 mg for oral dosing
Other Name: CORT118335

Drug: Placebo
Placebo tablets for oral dosing
Placebo Comparator: Placebo
Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive placebo once daily for 12 weeks.
 Drug: Placebo
Placebo tablets for oral dosing


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Relative change from Baseline in LFC (liver fat content) assessed by MRI-PDFF. [ Time Frame: Baseline Day 1 to Week 12 ]

Secondary Outcome Measures :
  1. Proportion of patients achieving a relative reduction in LFC of ≥30% by MRI-PDFF [ Time Frame: Baseline Day 1 to week 12 ]
  2. Change from Baseline in propeptide of type III collagen (pro-C3) [ Time Frame: Baseline Day 1 to week 12 ]
  3. Change from Baseline in enhanced liver fibrosis (ELF) score and its components (hyaluronic acid, tissue inhibitor of metalloproteinases-1 [TIMP-1], type III procollagen [PIIINP]) [ Time Frame: Baseline Day 1 to Week 12 ]
  4. Change from Baseline in aspartate aminotransferase (AST) [ Time Frame: Baseline Day 1 to Week 12 ]
  5. Change from Baseline in alanine aminotransferase (ALT) [ Time Frame: Baseline Day 1 to Week 12 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have a diagnosis of NASH based on a biopsy obtained within the last year OR
  • Have a diagnosis of presumed NASH based on blood tests and scans

Exclusion Criteria:

  • Have participated in another clinical trial within the last year and received active treatment for NASH
  • Have participated in another clinical trial for any other indication within the last 3 months
  • Are pregnant or lactating women
  • Have a BMI <18 kg/m2
  • Have had liver transplantation or plan to have liver transplantation during the study
  • Have type 1 diabetes or poorly controlled type 2 diabetes.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03823703


Locations
Layout table for location information
United States, Arizona
Site 207
Chandler, Arizona, United States, 85224
Site 208
Glendale, Arizona, United States, 85306
Site 209
Tucson, Arizona, United States, 85712
United States, California
Site 227
Los Angeles, California, United States, 90057
Site 214
Panorama City, California, United States, 91402
Site 233
Santa Ana, California, United States, 92704
United States, Florida
Site 234
Port Orange, Florida, United States, 32127
Site 210
Sarasota, Florida, United States, 34240
United States, Missouri
Site 228
Kansas City, Missouri, United States, 61434
United States, New York
Site 232
East Syracuse, New York, United States, 13057
United States, Texas
Site 211
Austin, Texas, United States, 78757
Site 213
Edinburg, Texas, United States, 78539
Site 215
Edinburg, Texas, United States, 78539
Site 212
San Antonio, Texas, United States, 78229
United States, Washington
Site 226
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Corcept Therapeutics
Investigators
Layout table for investigator information
Study Director: Ada Lee, MD Corcept Therapeutics
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Corcept Therapeutics
ClinicalTrials.gov Identifier: NCT03823703    
Other Study ID Numbers: CORT118335-860
First Posted: January 30, 2019    Key Record Dates
Last Update Posted: October 6, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Corcept Therapeutics:
Nonalcoholic Steatohepatitis
NASH
Nonalcoholic Fatty Liver Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
 Digestive System Diseases
Cortisone
Anti-Inflammatory Agents